SCHEMBL2296255

SCHEMBL2296255

O=C(CON=C1CCN(S(=O)(=O)c2cccc(C(F)(F)F)c2)CC1)Nc1ccccc1F

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
CHRNB2 P17787 2/20 0.48
CHRNB4 P30926 2/20 0.48
CHRNA3 P32297 2/20 0.48
CHRNA4 P43681 2/20 0.48
KMT2A Q03164 3/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
LMNA P02545 3/20 0.47
GAA P10253 3/20 0.47
MAPT P10636 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HSD17B10 Q99714 1/20 0.47
MEN1 O00255 1/20 0.46
RECQL P46063 1/20 0.46
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2295567 0.89 LMNA (0.47) ALDH1A1KMT2ALMNAGAAMAPT
SCHEMBL2295174 0.88 LMNA (0.58) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL2292594 0.88 ALDH1A1 (0.52) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL2291103 0.87 KMT2A (0.56) ALDH1A1CHRNB2CHRNB4CHRNA3CHRNA4
SCHEMBL2295416 0.86 KMT2A (0.54) ALDH1A1KMT2ALMNAGAAMAPT
SCHEMBL2294262 0.84 L3MBTL1 (0.47) ALDH1A1KMT2AL3MBTL1LMNAGAA
SCHEMBL2290350 0.84 LMNA (0.53) ALDH1A1KMT2AL3MBTL1LMNAGAA
SCHEMBL2292819 0.84 LMNA (0.55) ALDH1A1KMT2AL3MBTL1LMNAGAA
SCHEMBL8103247 0.84 LMNA (0.55) ALDH1A1KMT2ALMNAGAAMAPT
SCHEMBL12419494 0.84 KMT2A (0.45) ALDH1A1KMT2ALMNAGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2011-08-04 US disclosed
EP-2164326-A1 AMIDE COMPOUNDS AND THE USE THEREOF Euro-Celtique, S.A. (LU) 2010-03-24 EP disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed
WO-2008150447-A1 AMIDE COMPOUNDS AND THE USE THEREOF EURO-CELTIQUE S.A. (LU) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190300-A1 AMIDE COMPOUNDS AND THE USE THEREOF CACNA1E, CACNA1B, CACNA1S ALDH1A1 1349/4885CHRNB2 414/4885CHRNB4 404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.